I-Mab reports results for the quarter ended March 31 - Earnings Summary

NovaBridge Biosciences

15/05/2025 22:02

I-Mab IMAB.OQ reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of two analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -7 cents to -6 cents per share.

Reported revenue was zero​; analysts expected zero.

I-Mab's reported EPS for the quarter was a loss of 4 cents​.

The company reported a quarterly loss of $3.15 million.

I-Mab shares had risen by 7.1% this quarter and gained 3.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 40.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for I-Mab is $5.50

This summary was machine generated from LSEG data May 15 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.06
-0.03
Beat
Dec. 31 2024
-0.06
-0.08
Missed
Sep. 30 2024
-0.23
-0.25
Missed
Jun. 30 2024
-1.30
-0.46
Beat